03 May 2024 | 11:11 AM UTC
Niger: Elevated meningococcal disease activity reported in multiple areas, especially Niamey region, in early May
Elevated meningococcal disease activity reported in multiple areas in Niger, especially Niamey, in early May. Obtain vaccination.
Health officials have reported elevated meningococcal disease activity in multiple areas in Niger, with 2,012 total cases reported Jan. 1-April 21. This compared to 1,389 cases reported over a similar period in 2023. The Niamey region (52 cases per 100,000 population at risk) is most affected, followed by Agadez (11.5 cases per 100,000 population), Zinder (6.4 cases per 100,000 population) and Dosso (6.4 cases per 100,000 population). The WHO has implemented several interventions in response to the outbreak, including case management and the mobilization of resources to organize a vaccination campaign. This represents the most complete data available as of May 3.
Visit a doctor to ensure vaccination against meningococcal disease. Practice basic health precautions. Seek medical attention if symptoms develop within two weeks of being in affected areas.
Meningococcal disease is a significant public health problem in Africa, especially in countries that lie along the meningitis belt. Niger is located largely in the African meningitis belt, where the risk of infection is highest from January to June. The risk of infection in Niger exists nationwide, especially in poor and densely crowded areas.
Meningococcal disease, also called bacterial meningitis, is a bacterial disease that spreads through respiratory droplets created when an infected individual coughs, sneezes, or speaks. Disease transmission usually requires close or lengthy contact with an infected individual. Symptoms typically appear 3-4 days after exposure, but can develop up to 10 days after exposure. The most common symptoms of meningococcal disease are a stiff neck, high fever, sensitivity to light, confusion, headaches, and vomiting.
